BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 32231354)

  • 1. Decreasing fluconazole susceptibility of clinical South African Cryptococcus neoformans isolates over a decade.
    Naicker SD; Mpembe RS; Maphanga TG; Zulu TG; Desanto D; Wadula J; Mvelase N; Maluleka C; Reddy K; Dawood H; Maloba M; Govender NP;
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008137. PubMed ID: 32231354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.
    Nielsen K; Vedula P; Smith KD; Meya DB; Garvey EP; Hoekstra WJ; Schotzinger RJ; Boulware DR
    Med Mycol; 2017 Jun; 55(4):453-456. PubMed ID: 27664991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates obtained through population-based surveillance in South Africa in 2002-2003 and 2007-2008.
    Govender NP; Patel J; van Wyk M; Chiller TM; Lockhart SR;
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2606-11. PubMed ID: 21444707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
    Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
    Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
    Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
    Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Etests and Vitek 2 ® to broth microdilution for the susceptibility testing of Cryptococcus neoformans.
    Mahabeer Y; Chang CC; Naidu D; Dorasamy A; Lewin S; Ndung'u T; Moosa MY; French M; Mlisana K; Coovadia Y
    Diagn Microbiol Infect Dis; 2014 Dec; 80(4):294-8. PubMed ID: 25277745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E; Vitali LH; Kress MRVZ; Martinez R
    Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species.
    Bongomin F; Oladele RO; Gago S; Moore CB; Richardson MD
    Mycoses; 2018 May; 61(5):290-297. PubMed ID: 29377368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
    Abdel-Salam HA
    Mycoses; 2005 Sep; 48(5):327-32. PubMed ID: 16115103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro synergistic effect of minocycline combined with antifungals against Cryptococcus neoformans.
    Tan L; Shi H; Chen M; Wang Z; Yao Z; Sun Y
    J Mycol Med; 2022 Mar; 32(1):101227. PubMed ID: 34800920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.
    Smith KD; Achan B; Hullsiek KH; McDonald TR; Okagaki LH; Alhadab AA; Akampurira A; Rhein JR; Meya DB; Boulware DR; Nielsen K;
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7197-204. PubMed ID: 26324276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.
    Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
    Diagn Microbiol Infect Dis; 2011 Nov; 71(3):252-9. PubMed ID: 21917395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.
    Perkins A; Gomez-Lopez A; Mellado E; Rodriguez-Tudela JL; Cuenca-Estrella M
    J Antimicrob Chemother; 2005 Dec; 56(6):1144-7. PubMed ID: 16282208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluconazole and itraconazole susceptibility of clinical isolates of Cryptococcus neoformans at a tertiary care centre in India: a need for care.
    Datta K; Jain N; Sethi S; Rattan A; Casadevall A; Banerjee U
    J Antimicrob Chemother; 2003 Oct; 52(4):683-6. PubMed ID: 12951350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the
    Yang C; Bian Z; Blechert O; Deng F; Chen H; Li Y; Yang Y; Chen M; Zhan P
    Front Cell Infect Microbiol; 2021; 11():723251. PubMed ID: 34790585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular types of Cryptococcus neoformans and Cryptococcus gattii in Western Australia and correlation with antifungal susceptibility.
    Lee GA; Arthur I; Merritt A; Leung M
    Med Mycol; 2019 Nov; 57(8):1004-1010. PubMed ID: 30649538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.